

Ain Shams University Faculty of science

## Evaluation of the *Her-2/neu* gene expression level as a response to radiotherapy and hormonal therapy in breast cancer patients

Thesis

Submitted in Partial Fulfillment of the Requirements for the Master Degree of Science in Biochemistry

 $\mathcal{B}y$ 

Marwa Esmat Abd-El Baset Khalil B.Sc. Chemistry and Biochemistry (2006)

Ain shams University
Faculty of Sciences
Biochemistry Department
2015





## Evaluation of the *Her-2/neu* gene expression level as a response to radiotherapy and hormonal therapy in breast cancer patients

A thesis
Submitted in Partial Fulfillment of the Requirements for the
Master Degree of Science in Biochemistry

### $\mathcal{B}y$

#### Marwa Esmat Abd-El Baset Khalil

B.Sc. Chemistry and Biochemistry, (2006)

Under supervision of

#### Prof. Dr. Ahmed Osman Egiza Prof. Dr. Tarek Khaled Elmaghraby

Professor of Biochemistry and Head of Biochemistry Department Faculty of Science Ain Shams University

Professor of Molecular Biology National Center for Radiation Research & Technology Atomic Energy Authority

#### Dr. Eman Mossad Zaky

Assistant Professor of Clinical pathology South Egypt Cancer Institute Assiut University

#### **Department of Biochemistry**

Faculty of Science Ain Shams University

2015



صَّالَ وَالسَّالَ الْعَظَمِينَ،

#### **Biography**

Name: Marwa Esmat Abdel-Baset Khalil

**Date of Graduation:** 2006

**Degree Awarded** 

**for Graduation**: B.Sc. of Biochemistry (excellent)

**Date of registration** 

to Master Degree: January 2012

**Occupation**: Chemistry Specialist at Egyptian Atomic

**Energy Authority** 



"رَبِّ أَوْزِعْنِي أَنْ أَشْكُرَ نِعْمَتَكَ الَّتِي أَنْعَمْتَ عَلَيَّ وَعَلَى وَعَلَى وَعَلَى وَالْدَيَّ وَأَنْ أَعْمَلَ صَالِحًا تَرْضَاهُ وَأَدْخِلْنِي بِرَحْمَتِكَ فِي وَالْدَيِّ وَأَنْ أَعْمَلَ صَالِحًا تَرْضَاهُ وَأَدْخِلْنِي بِرَحْمَتِكَ فِي عِبَادِكَ الصَّالِحِينِ"

# My work is dedicated to: Allah and hope to accept it from me

"A special thanks to my family. Words cannot express how grateful I am to my mother and father for all of the sacrifices that you have made on my behalf. Your prayer for me was what sustained me thus far.

I would also like to thank my sister and my brother who supported me in writing, and encouraged me to strive towards my goal. "

Marwa Esmat Abd El Baset

### Acknowledgments

We thank God greatly for his kindness and blessing which He had given us to conduct this piece of work.

This work would not be performed without the support of the **Academy of Scientific Research and Technology** grant (Scientists for Next Generation (SNG)). I wish to thank each one working with this great project.

I am greatly honored to express my sincere gratitude to Prof. Dr. Ahmed Osman Egiza, Professor of Biochemistry, and head of Biochemistry Department, Faculty of Science, Ain Shams University, Egypt, for his kind supervision, moral support, ever helping and guidance and for his valuable suggestions from time to time.

I would like also to express my honest and deep gratitude to my supervisor my supervisor Prof. Dr. Tarek Almaghraby, the head of the molecular biology lab, Radiobiology department, National Center for Radiation Research and Technology (NCRRT), The Egyptian Atomic energy Authority (EAEA), for suggesting the plane of the work and providing all the facilities for the accomplishment of this work as well as his continuous valuable guidance and helpful discussion throughout all tages of the study and also for handwriting of this manuscript.

My thanks to Dr. **Eman Mossad Zaky**, Assistant Professor of Clinical pathology, south Egypt, for her sincere help, her kind assistance and guidance throughout this study that brought it to light.

I would like also to thanks **Dr. Sanaa Abdel-Hamid.**, Lecturer of molecular biology, (NCRRT), for her help throughout this work.

I extend my thanks to radiation biology department and to all my colleagues (NCRRI) for their help and encouragement.

I am extremely grateful to my family for their kindness, toleration, and motivation, without their support and helpfulness; this work would never have come to light.

Marwa Esmat

## List of contents

Ackno	wledgments	i
List of	Contents	ii
List of	Abbreviations	vi
List of	Figures	X
	Tables	xii
	act	1-2
	uction	3-6
	f Work	7
	y of literature	8
1.	Breast cancer definition	8
1.1.	Epidemiology	8
1.2.	Anatomy of the breast	9
1.3.	Breast cancer's development	10
1.4.	Types of Tumor in the breast	11
1.4.1.	Benign tumor	11
1.4.2.	Malignant tumors	11
2.	Risk factors (Etiology)	12
2.1.	Sex and Race	12
2.2.	Age	12
2.3.	A personal or family history of breast cancer	13
2.4.	Genetic mutations in the BRCA1 or BRCA2 genes	13
2.5.	Prolonged exposure to hormones	13
2.6.	A history of benign breast diseases	14
2.7.	Ionizing radiation	14
2.8.	Lifestyle factors	14
3.	Classification of breast cancer.	14
3.1.	Histological Classifications of Breast Cancer Subtypes	15
3.2.	Molecular Classifications of Breast Cancer Subtypes	17
4.	Staging	21
5.	Grading	22

6.	Prognostic and predictive factors in breast cancer	23
6.1.	Prognostic factor	24
6.2.	Predictive factor	24
7.	Tumor markers of breast cancer	25
7.1.	Molecular biomarkers of breast cancer	26
7.1.1.	Steroid hormone receptors	28
7.1.1.1.	Human Estrogen receptor(ER)	29
7.1.1.1.1.	ER Action and Function.	29
7.1.1.1.2.	Mechanism of ER-Ligand Interaction	33
7.1.1.1.3.	Regulation of Signal Transduction Pathways	35
7.1.1.1.4.	Implication of Estrogen in breast cancer risk	37
7.1.1.2.	Progesterone Receptor (PgR, PR)	38
7.1.1.2.1.	Significance of PR in breast cancer.	39
7.2.	Significance of combined ER and PR in breast cancer	40
7.3.	Methods of detection the hormone receptors	41
7.1.2.	The <i>c-erbB2/neu</i> oncogene, or <i>HER2/neu</i>	42
7.1.2.1.	Her-2/neu gene	43
7.1.2.2.	Her-2/neu biology	44
7.1.2.3.	The Her receptor family structure and its ligand	45
7.1.2.4.	Mechanism of Her-2/neu activation	51
7.1.2.5.	Her-2/neu expression.	52
7.1.2.5.1.	HER-2/neu normal expression	52
7.1.2.5.2.	HER-2/neu over-expression	52
7.1.2.6.	Her-2/neu testing techniques	54
7.1.2.6.1.	IHC	54
7.1.2.6.2.	Real-time quantitative polymerase chain reaction	55
7.1.2.7.	Serum Her-2/neu	56
7.1.2.7.1.	Changes in serum <i>HER-2/neu</i> levels	57
7.1.2.8.	Clinical aspects of Her-2/neu	58
7.1.2.8.1.	HER-2/neu in breast cancer prognosis	58
7.1.2.8.2.	HER-2/neu as a predictive factor	58
8.	Treatment of breast cancer	59
8.1.	Local therapy	59
8.1.1.	Surgery	60
8.1.2.	Radiation therapy	61
8.2.	Systemic therapy	59

8.2.1.	Chemotherapy	62
8.2.2.	Hormonal therapy	65
8.2.2.1.	Tamoxifen	66
8.2.2.2.	Aromatase inhibitors	66
8.2.3.	Targeted Therapy	67
<ol> <li>Subject</li> </ol>	Breast cancer Recurrence  ct and methods	68 69
J		
2.1.	Patient's subjects	69
2.1.1.	Sampling	70
2.1.1.1.	Blood samples	70
2.1.1.2.	Tissue samples	71
2.2.	Methods	71
2.2.1.	Immunohistochemistery studies	71
2.2.1.1.	Immunostaining for ER&PR	71
2.2.1.2.	Immunostaining for HER-2	76
2.3.	Molecular studies	78
2.3.1.	DNA extraction.	79
2.3.1.1.	Assessment of her-2/neu gene amplification using real time-PCR	83
2.3.1.1.1.	Quantification of Her-2/neu gene amplification	84
2.3.2.	Determination of Her-2/neu expression	85
2.3.2.1.	RNA extraction.	85
2.3.2.2.	Synthesis cDNA via reverse transcription	88
2.3.2.3.	Quantitative by real time-PCR	90
2.3.3.	Determination of cDNA quality	93
2.3.3.1.	Gel electrophoresis	93
2.4.	Statistical analysis	94
3. Result	ts	95
3.1.	Clinical presentation	95
3.1.1.	Breast cancer patients	95
3.2.	Immunohistochemical analysis (IHC)	96
3.2.1.	Immunostaining for Estrogen and progesterone receptors	98
3.2.1.1.	Estrogen receptor(ER) positive and negative	98